ASCO: FOLFOX Noninferior to Chemoradiotherapy for Overall Survival in Rectal Cancer
FRIDAY, June 9, 2023 -- Neoadjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is noninferior to preoperative chemoradiotherapy with respect to overall survival for patients with locally advanced rectal cancer who are...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Eloxatin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pharmaceuticals | Rectal Cancers